Abstract
The exploration of nanocrystal technology is currently receiving significant attention in various fields, including therapeutic formulation, clinical formulation, in-vivo and in-vitro correlation research, and related investigations. The domain of nanocrystals in pharmaceutical delivery has received significant interest as a potential solution for the difficulties associated with medications that have low solubility. The nanocrystals demonstrate promise in improving solubility and bioavailability, presenting a potential resolution to significant challenges. Significantly, nanocrystals have exhibited efficacy in the context of oral administration, showcasing prompt absorption due to their quick breakdown, hence fitting with the requirements of medications that necessitate fast commencement of action. In addition, the adaptability of drug nanocrystals encompasses several methods of administration, including oral, parenteral, ophthalmic, cutaneous, pulmonary, and targeted delivery modalities. The observed consistency can be ascribed to the increased solubility of nanocrystals of the medicine, which effectively counteracts the influence of food on the absorption of the drug. Surface modification tactics have a significant influence on insoluble medicines by enhancing hydrophilicity and reducing plasma protein adsorption on the crystal surface. The surface properties of nanocrystals are modified through the utilization of specific surfactants and polymers, which are subsequently incorporated into polymer solutions via high-pressure homogenization procedures. This article encompasses an examination of the drug distribution mechanism, the nanocrystal formulation technology, the therapeutic applications, the potential future developments, and the challenges associated with the solubility and bioavailability of tailored nanocrystals, as discussed in this article. Consequently, it possesses the capacity to provide guidance for future investigations pertaining to nanocrystal technology.
Keywords: Nanocrystals, solubility, bioavailability, drug delivery, poorly soluble drugs, homogenization.
[http://dx.doi.org/10.2174/156720111795767988] [PMID: 21453258]
[http://dx.doi.org/10.1016/j.ajps.2014.08.005]
[http://dx.doi.org/10.1016/B978-0-12-813741-3.00011-X]
[http://dx.doi.org/10.1007/978-981-10-3647-7_9]
[http://dx.doi.org/10.22270/jddt.v8i5.1946]
[http://dx.doi.org/10.1007/s11051-008-9357-4]
[http://dx.doi.org/10.1016/j.addr.2018.05.002]
[http://dx.doi.org/10.1016/j.drudis.2018.01.016]
[http://dx.doi.org/10.4155/tde-2020-0016] [PMID: 32157960]
[http://dx.doi.org/10.3390/pharmaceutics10030134] [PMID: 30134537]
[http://dx.doi.org/10.1002/btm2.10122] [PMID: 30680314]
[PMID: 18990939]
[http://dx.doi.org/10.3402/nano.v2i0.5883] [PMID: 22110867]
[http://dx.doi.org/10.1007/s11095-012-0889-z] [PMID: 23073665]
[http://dx.doi.org/10.3390/polym14040658] [PMID: 35215570]
[http://dx.doi.org/10.1016/j.ijpharm.2021.120623] [PMID: 33892058]
[http://dx.doi.org/10.1016/j.colsurfb.2023.113231] [PMID: 36907135]
[http://dx.doi.org/10.1016/j.msec.2020.110895] [PMID: 32409052]
[http://dx.doi.org/10.3390/pharmaceutics13030421] [PMID: 33804727]
[http://dx.doi.org/10.1007/s40121-020-00382-7] [PMID: 33523419]
[http://dx.doi.org/10.1002/smtd.201900440]
[http://dx.doi.org/10.2217/nnm-2020-0034] [PMID: 32452262]
[http://dx.doi.org/10.1002/smtd.202000419]
[http://dx.doi.org/10.1007/s40735-022-00683-z]
[http://dx.doi.org/10.1021/acsnano.1c07856] [PMID: 34694776]
[http://dx.doi.org/10.1039/C8NR02278J] [PMID: 29926865]
[http://dx.doi.org/10.3390/ph16070908] [PMID: 37513820]
[http://dx.doi.org/10.1155/2014/265754] [PMID: 26556191]
[http://dx.doi.org/10.1007/s11095-010-0323-3] [PMID: 21086152]
[http://dx.doi.org/10.1016/j.ijpharm.2013.01.019] [PMID: 23333709]
[http://dx.doi.org/10.4155/ebo.13.398]
[http://dx.doi.org/10.1016/B978-0-323-42868-2.00007-3]
[http://dx.doi.org/10.1016/j.phyplu.2022.100257]
[http://dx.doi.org/10.1016/j.ijbiomac.2020.01.302] [PMID: 32018009]
[http://dx.doi.org/10.1016/j.ijpharm.2011.05.008] [PMID: 21596122]
[http://dx.doi.org/10.1016/j.jconrel.2012.03.013] [PMID: 22465393]
[http://dx.doi.org/10.1039/c2nr30260h] [PMID: 22565323]
[http://dx.doi.org/10.1016/S0169-409X(02)00118-7] [PMID: 12460720]
[http://dx.doi.org/10.1016/j.ijpharm.2007.03.009] [PMID: 17428627]